PDF icon Download PDF
Dtsch Med Wochenschr 2003; 128(18): 1007-1012
DOI: 10.1055/s-2003-38957
Übersichten
© Georg Thieme Verlag Stuttgart · New York

Die natriuretischen Peptide BNP und NT-pro-BNP - die „neuen Troponine” der Herzinsuffizienz?

Natriuretic peptides BNP and NT-pro-BNP - the „new troponins“ for estimation of heart failure?R. Pfister1 , E. Erdmann1 , C. A. Schneider1
  • 1Klinik III für Innere Medizin, (Direktor: Prof. Dr. med. E. Erdmann), Universität zu Köln
Further Information

Publication History

eingereicht: 10.1.2003

akzeptiert: 27.2.2003

Publication Date:
30 April 2003 (online)

Also available ateRef
   Permissions and Reprints
Preview

Die chronische Herzinsuffizienz hat in den westlichen Ländern eine zunehmende Prävalenz und im fortgeschrittenen Stadium eine hohe Mortalität [6]. Wenngleich das pathophysiologische Verständnis der Herzinsuffizienz auch auf molekularer Ebene wächst, ist bisher noch kein aussagekräftiger, einfach bestimmbarer Marker wie beispielsweise die Troponine, bei der akuten Myokardschädigung bekannt.

Die meisten bisher untersuchten Serummarker der Herzinsuffizienz wie Renin, Norepinephrin oder Endothelin, erwiesen sich aufgrund ihrer In-vitro-Instabilität oder der breiten physiologischen Streuung der Hormonwerte als ungeeignet für die diagnostische Routine [20]. In den aktuellen Leitlinien der großen europäischen und amerikanischen kardiologischen Fachgesellschaften findet erstmals das natriuretische Peptid Typ-B (BNP) Erwähnung als diagnostischer Parameter der Herzinsuffizienz [16] [35] . Daneben zeigen neuere Studienergebnisse bei verschiedenen kardiologischen Erkrankungen eine gute prognostische Bedeutung von BNP, was z.B für die Kontrolle einer medikamentösen Therapie genutzt werden kann. Ziel dieser Arbeit ist die Bewertung des BNP als klinischer Routineparameter.

Literatur

  • 1 Berendes E, Van Aken H, Raufhake C, Schmidt C, Assmann G, Walter M. Differential secretion of atrial and brain natriuretic peptide in critically ill patients.  Anesth Analg. 2001;  93 676-682
    Search in Google Scholar
  • 2 Berger R, Huelsman M, Strecker K. et al . B-type natriuretic peptide predicts sudden death in patients with chronic heart failure.  Circulation. 2002;  105 2392-2397
    Search in Google Scholar
  • 3 Cataliotti A, Malatino L S, Jougasaki M. et al . Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling.  Mayo Clin Proc. 2001;  76 1111-1119
    Search in Google Scholar
  • 4 Chen H H, Burnett J C. Natriuretic peptides in the pathophysiology of congestive heart failure.  Curr Cardiol Rep. 2000;  2 198-205
    Search in Google Scholar
  • 5 Cowie M R, Struthers A D, Wood D A. et al . Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care.  Lancet. 1997;  350 1349-1353
    Search in Google Scholar
  • 6 Cowie M R, Wood D A, Coats A J. et al . Incidence and aetiology of heart failure: a population-based study.  Eur Heart J. 1999;  20 421-428
    Search in Google Scholar
  • 7 Dao Q, Krishnaswamy P, Kazanegra R. et al . Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting.  J Am Coll Cardiol. 2001;  37 379-385
    Search in Google Scholar
  • 8 Davis M, Espiner E, Richards G. et al . Plasma brain natriuretic peptide in assessment of acute dyspnoea.  Lancet. 1994;  343 440-444
    Search in Google Scholar
  • 9 de Lemos J A, Morrow D A, Bentley J H. et al . The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes.  N Engl J Med. 2001;  345 1014-1021
    Search in Google Scholar
  • 10 Del Ry S, Giannessi D, Clerico A. Plasma brain natriuretic peptide measured by fully-automated immunoassay and by immunoradiometric assay compared.  Clin Chem Lab Med. 2001;  39 446-450
    Search in Google Scholar
  • 11 Hammerer-Lercher A, Neubauer E, Muller S, Pachinger O, Puschendorf B, Mair J. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction.  Clin Chim Acta. 2001;  310 193-197
    Search in Google Scholar
  • 12 Hirata Y, Matsumoto A, Aoyagi T. et al . Measurement of plasma brain natriuretic peptide level as a guide for cardiac overload.  Cardiovasc Res. 2001;  51 585-591
    Search in Google Scholar
  • 13 Hobbs F D, Davis R C, Roalfe A K, Hare R, Davies M K, Kenkre J E. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations.  BMJ. 2002;  324 1498
    Search in Google Scholar
  • 14 Hunt P J, Richards A M, Nicholls M G, Yandle T G, Doughty R N, Espiner E A. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT- PROBNP): a new marker of cardiac impairment.  Clin Endocrinol (Oxf). 1997;  47 287-296
    Search in Google Scholar
  • 15 Hunt P J, Yandle T G, Nicholls M G, Richards A M, Espiner E A. The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma.  Biochem Biophys Res Commun. 1995;  214 1175-1183
    Search in Google Scholar
  • 16 Hunt S A, Baker D W, Chin M H. et al . ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure).  J Am Coll Cardiol. 2001;  38 2101-2113
    Search in Google Scholar
  • 17 Jensen K T, Carstens J, Ivarsen P, Pedersen E B. A new, fast and reliable radioimmunoassay of brain natriuretic peptide in human plasma. Reference values in healthy subjects and in patients with different diseases.  Scand J Clin Lab Invest. 1997;  57 529-540
    Search in Google Scholar
  • 18 Karl J, Borgya A, Gallusser A. et al . Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit.  Scand J Clin Lab Invest Suppl. 1999;  230 177-181
    Search in Google Scholar
  • 19 Kazanegra R, Cheng V, Garcia A. et al . A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study.  J Card Fail. 2001;  7 21-29
    Search in Google Scholar
  • 20 Kjaer A, Hesse B. Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives.  Clin Physiol. 2001;  21 661-672
    Search in Google Scholar
  • 21 Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, von Scheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure.  J Am Coll Cardiol. 2001;  38 1934-1941
    Search in Google Scholar
  • 22 Krishnaswamy P, Lubien E, Clopton P. et al . Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction.  Am J Med. 2001;  111 274-279
    Search in Google Scholar
  • 23 Latini R, Masson S, Anand I. et al . Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).  Circulation . 2002;  106 2454-2458
    Search in Google Scholar
  • 24 Lubien E, DeMaria A, Krishnaswamy P. et al . Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings.  Circulation. 2002;  105 595-601
    Search in Google Scholar
  • 25 Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction.  Am Heart J. 1998;  135 825-832
    Search in Google Scholar
  • 26 Maisel A S, Krishnaswamy P, Nowak R M. et al . Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure.  N Engl J Med. 2002;  347 161-167
    Search in Google Scholar
  • 27 McCullough P A, Nowak R M, McCord J. et al . B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study.  Circulation. 2002;  106 416-422
    Search in Google Scholar
  • 28 McDonagh T A, Cunningham A D, Morrison C E. et al . Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population.  Heart. 2001;  86 21-26
    Search in Google Scholar
  • 29 McDonagh T A, Robb S D, Murdoch D R. et al . Biochemical detection of left-ventricular systolic dysfunction.  Lancet. 1998;  351 9-13
    Search in Google Scholar
  • 30 McNairy M, Gardetto N, Clopton P. et al . Stability of B-type natriuretic peptide levels during exercise in patients with congestive heart failure: implications for outpatient monitoring with B-type natriuretic peptide.  Am Heart J. 2002;  143 406-411
    Search in Google Scholar
  • 31 Morrison L K, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea.  J Am Coll Cardiol. 2002;  39 202-209
    Search in Google Scholar
  • 32 Mukoyama M, Nakao K, Obata K. et al . Augmented secretion of brain natriuretic peptide in acute myocardial infarction.  Biochem Biophys Res Commun. 1991;  180 431-436
    Search in Google Scholar
  • 33 Murdoch D R, Byrne J, McDonagh T, Morton J J, McMurray J J. Measurement of brain natriuretic peptide.  Lancet. 1996;  348 1589
    Search in Google Scholar
  • 34 Pfister R, Scholz M, Wielckens K, Erdmann E, Schneider C A. The rank of natriuretic peptides NT-pro-BNP and BNP for the estimation of left-ventricular volume and function.  Dtsch Med Wochenschr. 2002;  127 2605-2609
    Search in Google Scholar
  • 35 Remme W J, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure.  Eur Heart J. 2001;  22 1527-1560
    Search in Google Scholar
  • 36 Richards A M, Doughty R, Nicholls M G. et al. Australia-New Zealand Heart Failure Group . Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction.  Circulation. 1999;  99 786-792
    Search in Google Scholar
  • 37 Sayama H, Nakamura Y, Saito N, Kinoshita M, Suda M. Relationship between left ventricular geometry and brain natriuretic peptide levels in elderly subjects.  Gerontology. 2000;  46 71-77
    Search in Google Scholar
  • 38 Smith H, Pickering R M, Struthers A, Simpson I, Mant D. Biochemical diagnosis of ventricular dysfunction in elderly patients in general practice: observational study.  BMJ. 2000;  320 906-908
    Search in Google Scholar
  • 39 Smith R A. Breast cancer screening among women younger than age 50: a current assessment of the issues.  CA Cancer J Clin. 2000;  50 312-336
    Search in Google Scholar
  • 40 Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain.  Nature. 1988;  332 78-81
    Search in Google Scholar
  • 41 Talwar S, Squire I B, Downie P F, Davies J E, Ng L L. Plasma N terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina.  Heart. 2000;  84 421-424
    Search in Google Scholar
  • 42 Troughton R W, Frampton C M, Yandle T G, Espiner E A, Nicholls M G, Richards A M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations.  Lancet. 2000;  355 1126-1130
    Search in Google Scholar
  • 43 Vasan R S, Benjamin E J, Larson M G. et al . Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the framingham heart study.  JAMA. 2002;  288 1252-1259
    Search in Google Scholar

Priv.-Doz. Dr. med. Christian Alfons Schneider

Klinik III für Innere Medizin, Universität zu Köln

Josef-Stelzmann Str. 9

50924 Köln

Phone: 0221/4786207

Fax: 0221/4783763

Email: christian.schneider@medizin.uni-koeln.de